The positive results from the Phase 3 CheckMate -9DW trial are likely to boost investor confidence in Bristol Myers Squibb's oncology portfolio, potentially leading to an increase in stock price. The improved overall survival rates for Opdivo and Yervoy in advanced hepatocellular carcinoma patients highlight the effectiveness of the treatment, which could drive higher revenues and market share.